# Relmada Therapeutics, Inc.: Form 8-K, filed Mar 20, 2026

- Company: [Relmada Therapeutics, Inc.](/companies/rlmd.md) (CIK 1553643)
- Form: 8-K
- Filed: 2026-03-20
- Accepted by EDGAR: Mar 20, 2026, 16:52 ET
- Period: 2026-03-19
- Accession: 0001213900-26-032403
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/ea0282688-8k_relmada.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/

## Items reported

- Item 2.02: Results of operations
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/ea0282688-8k_relmada.htm

Filed Mar 20, 2026.
Source: SEC EDGAR, the filing index for accession 0001213900-26-032403. Last ingested by Listed: Oct 24, 2026, 15:13 ET. No prices; not investment advice.